B-cell epitope dsDNA

Vantictumab

Anti-Fzd7 (vantictumab, OMP-18R5) Vantictumab is OncoMed’s lead program in the Wnt pathway. Screened against the Frizzled 7 receptor, the antibody binds a conserved epitope on five of the Fr...

Antibody classes

An antibody, also known as an immunoglobulin, is a large Y-shaped protein used by the immune system to identify and neutralize foreign objects such as bacteria and viruses. The antibody recognizes a...

Her2 Receptor Antagonists

Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab)...

p38 mitogen activated protein kinase MAPK Inhibitors

The next generation of p38 mitogen-activated protein kinase (MAPK) inhibitors has reached clinical proof-of-concept studies in phase II in a broad range of indications. While the previous generation o...

Pharmaceutical Research: RAFTsomes Containing Epitope-MHC-II Complexes Mediated CD4+ T Cell Activation and Antigen-Specific Immune Responses

Type: Original PaperPurposeTo develop a liposome formulation incorporating antigen-presenting cells (APCs) membrane microdomains with enriched epitope/MHC complexes to evaluate the activities of these...

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Characterization of human monoclonal antibodies is providing considerable insight into mechanisms of broad HIV-1 neutralization. Here we report an HIV-1 gp41 membrane-proximal external region (MPER)-s...

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

B-cell antigen receptor (BCR) expression is an important feature of chronic lymphocytic leukaemia (CLL), one of the most prevalent B-cell neoplasias in Western countries. The presence of stereotyped a...

Autoimmunity: New insights into functional effects of the shared epitope

Glomerular diseases: MPO CD4+ T-cell epitope induces glomerulonephritis

Vasculitis: Epitope specificity responsible for MPO-ANCA pathogenicity

Exogenous, TAP-independent lysosomal presentation of a respiratory syncytial virus CTL epitope

Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence.

Antibodies to two crucial regions, the third variable loop (V3) of gp120 and the membrane-proximal external region (MPER) of gp41 are important for HIV-1 neutralization. We here evaluated the relative...

Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.

Peptide mimics of epitopes for pathogen-specific antibodies present in patient sera can be selected based on the phage display technology. Such mimotopes potentially represent vaccine candidates in ca...

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen.

Induction of neutralizing antibodies to prevent HIV infection, especially at the mucosa, is a critical goal of future vaccines. In this study, we have designed chimeric HIV-gag virus-like particles (V...

Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.

: 2F5 and 4E10 are two broadly neutralizing monoclonal antibodies (mAbs) targeting the membrane proximal external region (MPER) of HIV-1 gp41 envelope protein. This region, which contacts the viral me...

Induction of Antibodies Binding to the Membrane Proximal External Region of gp36 of HIV-2.

Objective: The ability to induce neutralizing antibodies may be the most important feature of an antiretroviral vaccine, preventing infection of target cells and subsequent integration of the virus in...